DMNB Adopts DNASTAR Lasergene Software
News Sep 05, 2013
DNASTAR has announced that Dalhousie Medicine New Brunswick (DMNB) has entered into an agreement supporting an enterprise-wide site license of DNASTAR Lasergene software for genome sequence assembly and analysis.
The license provides access to the DNASTAR software for all faculty, staff and students of DMNB.
Dr. Keith Brunt, assistant professor at Dalhousie Medicine New Brunswick said, “Until we entered into this agreement, we didn’t have much experience with DNASTAR or their Lasergene software. The more time we spent using the software and the more we learned about its capabilities, the more impressed we were with it. By signing this agreement, we provide access to outstanding software for all of our scientists, faculty, staff and students at a very reasonable cost. This software will help in the training of a new generation of physicians and is a step toward patient tailored therapy. This agreement will help support the future success and growth of our program.”
Tom Schwei, Vice President and General Manager of DNASTAR, stated, “We are pleased to have entered into this agreement with Dalhousie Medicine New Brunswick. Our company was founded from an academic research environment and we continue to focus on ensuring we are serving the academic market well. We are particularly pleased to have DMNB as a customer, as their focus on medicine correlates well with a growing area of focus for our future software development. We appreciate the trust placed in our tools and company by DMNB’s management and we look forward to continuing to meet the organization’s sequence assembly and analysis software needs in the future.”
Financial terms of the arrangement were not disclosed.
Towards Personalized Medicine: One Type of Data is Not EnoughNews
To understand the biology of diseased organs researchers use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types. A new computational method jointly analyses different types of molecular data and disentangles the sources of disease variability to guide personalized treatment.READ MORE
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE